4 Aug 2026Open access
Pharmacokinetics of abacavir and lamivudine in infants living with HIV with and without rifampicin co-treatmentPublisher siteJournal of Antimicrobial Chemotherapy, HIV/AIDS drug development and treatment
UniversitiesVeronica Mulenga
Active, last published 2026
In hiv/aids drug development and treatment
Veronica
Mulenga
Scholar“Research focused on HIV/AIDS drug development and treatment and adjacent fields.”
Claim Your Profile22
H-index
2.0k
Citations
Veronica has not officially claimed their profile. If you are Veronica, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
eronica Mulenga is a researcher working on HIV/AIDS drug development and treatment. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Veronica's work has been cited 1,975 times across 2 active years. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
HIV/AIDS drug development and treatment×40HIV/AIDS Research and Interventions×32HIV-related health complications and treatments×19Tuberculosis Research and Epidemiology×15HIV Research and Treatment×13
04 · Where I am
Affiliations
Affiliation details will appear once this profile is updated.
Research themes (UN SDGs)
05 · Selected work
Recent publications
9 works1 Jul 2026Open access1cites
Oral step-down, optimal drug, and total duration of antibiotic treatment in African children hospitalised with severe community-acquired pneumonia (PediCAP): a factorial randomised controlled trialPublisher siteThe Lancet, Pneumonia and Respiratory Infections
1 Jul 2026Open access
Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trialPublisher siteThe Lancet, Cytomegalovirus and herpesvirus research
17 Jun 2026Open access
Performance of five risk stratification tools for paediatric pneumonia against WHO scores using data from the PediCAP trial in sub-Saharan AfricaPublisher sitemedRxiv, Pneumonia and Respiratory Infections
22 May 2026Open access
Impact of co-amoxiclav versus amoxicillin on the gastrointestinal microbiota in sub-Saharan children hospitalized with pneumoniaPublisher sitenpj Antimicrobials and Resistance, Pneumonia and Respiratory Infections
1 Apr 2026Open access
Pharmacokinetics and pharmacodynamics of valganciclovir in infants with severe HIV-associated pneumonia in Africa: a sub-study of the EMPIRICAL randomised controlled trialPublisher siteEClinicalMedicine, HIV/AIDS drug development and treatment
20 Sept 2024Open access4cites
Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIVPublisher siteJournal of Antimicrobial Chemotherapy, HIV/AIDS drug development and treatment
21 Apr 2024Open access3cites
Second-line tenofovir alafenamide for children with HIV in AfricaPublisher siteExpert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Veronica?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you